For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug
Kurzinformation



inkl. MwSt. Versandinformationen
Artikel zZt. nicht lieferbar
Artikel zZt. nicht lieferbar

Beschreibung
For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team-denied their share of the profits-went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks-and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine. von Vardi, Nathan
Produktdetails

So garantieren wir Dir zu jeder Zeit Premiumqualität.
Über den Autor
Nathan Vardi is a managing editor at MarketWatch and former senior editor at Forbes. He writes about big money investors, hedge funds, private equity firms, and the intersection of Wall Street and biopharma. He lives in Edgemont, New York.
- Hardcover
- 140 Seiten
- Erschienen 2018
- Wharton School Press
- Hardcover
- 304 Seiten
- Erschienen 2017
- LIGHTNING SOURCE INC
- Hardcover
- 416 Seiten
- Erschienen 2005
- Jossey-Bass
- Kartoniert
- 272 Seiten
- Erschienen 2019
- Crown
- Hardcover
- 464 Seiten
- Erschienen 2024
- Wiley
- Hardcover
- 226 Seiten
- Erschienen 1999
- Wiley
- Hardcover -
- Wiley John + Sons
- Taschenbuch
- 281 Seiten
- Erschienen 1999
- University of California Press
- Kartoniert
- 272 Seiten
- Erschienen 2006
- Bold Type Books
- hardcover -
- Erschienen 2012
- Basel: Roche Editiones
- Kartoniert
- 384 Seiten
- Erschienen 2001
- Crown Currency
- Hardcover
- 140 Seiten
- Erschienen 2018
- Wharton School Press